Spotlight on pomalidomide: could less be more?

por Zander, T, Aebi, S, Pabst, T, Renner, C, Driessen, C
Publicado 2017

Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance

por Kraus, M, Bader, J, Overkleeft, H, Driessen, C
Publicado 2013

The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways

por Besse, L, Kraus, M, Besse, A, Bader, J, Silzle, T, Mehrling, T, Driessen, C
Publicado 2017

Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patients: The introduction of a new measure

por Driessen, C. M. L., de Kleine-Bolt, K. M. E., Vingerhoets, A. J. J. M., Mols, F., Vreugdenhil, G.
Publicado 2011

Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma

por Besse, A, Stolze, S C, Rasche, L, Weinhold, N, Morgan, G J, Kraus, M, Bader, J, Overkleeft, H S, Besse, L, Driessen, C
Publicado 2018

Splenic size after division of the short gastric vessels in Nissen fundoplication in children

por Driessen, C., Paulus, G. F., Robben, S. G., Tjon a Ten, W. E., Van den Neucker, A., Verhoeven, B. H., Van Heurn, L. W. E.
Publicado 2011

Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10)

por Hitz, F., Kraus, M., Pabst, T., Hess, D., Besse, L., Silzle, T., Novak, U., Seipel, K., Rondeau, S., Stüdeli, S., Vilei, S. Berardi, Samaras, P., Mey, U., Driessen, C.
Publicado 2019

Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism

por Soriano, G P, Besse, L, Li, N, Kraus, M, Besse, A, Meeuwenoord, N, Bader, J, Everts, B, den Dulk, H, Overkleeft, H S, Florea, B I, Driessen, C
Publicado 2016

Prospective practice survey of management of cetuximab-related skin reactions

por Lugtenberg, R. T., Boers-Doets, C. B., Witteveen, P. O., van Herpen, C. M. L., Wymenga, A. N. M., de Groot, J. W. B., Hoeben, A., del Grande, C., van Doorn, B., Koldenhof, J. J., Driessen, C. M. L., Gelderblom, H.
Publicado 2020

P45 HIGH-DOSE CARFILZOMIB ACHIEVES SUPERIOR ANTI-TUMOR ACTIVITY OVER LOW-DOSE AND RECAPTURES RESPONSE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA RESISTANT TO LOW-DOSE CARFILZOMIB BY C...

por Zhou, X., Besse, A., Peter, J., Steinhardt, M. J., Vogt, C., Nerreter, S., Teufel, E., Stanojkovska, E., Xiao, X., Hornburger, H., Haertle, L., Mendez Lopez, M., Munawar, U., Riedel, A., Han, S., Maurits, E., Overkleeft, H. S., Florea, B., Einsele, H., Kortüm, K. M., Driessen, C., Besse, L., Rasche, L.
Publicado 2023